Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropivacaine QLB2 vs Intrathecal Morphine in C-Section
NCT04755712Phase 4Completed
- Sponsor
- Ramsay Santé
- Start
- Mar 2021
- Primary completion
- Oct 2022
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ropivacaine hydrochloride liposomal suspension injection in postoperative pain (2 arms), sponsored by Ramsay Santé. Primary endpoint: Cumulative quantity of morphine received postoperatively via pump at 1 day. Started Mar 2021; status: completed.
02
Drugs
ropivacaine hydrochloride liposomal suspension injection
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT04755712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04755712.